CAZANAT (Cabozantinib) is a tyrosine kinase inhibitor that prevents tumour growth and angiogenesis by blocking multiple receptors including MET, VEGFR, and RET. These receptors are involved in tumour proliferation, metastasis, and survival.
Recommended for:
Progressive renal cell carcinoma, hepatocellular carcinoma, medullary thyroid carcinoma.
Taken orally without chewing, on an empty stomach or two hours after a meal. Dosage and duration of treatment are determined by the physician depending on the patient’s condition and response to therapy.
Contraindications:
Side effects:
